Andy Geall

Andrew J. Geall, Ph.D.

Vice President, Formulations & Chemistry

Andrew J. Geall is the Vice President of Formulations and Chemistry at Avidity Biosciences in La Jolla, CA.  He has undergraduate degrees in Chemical Engineering and Pharmacy and completed his Ph.D. in gene delivery at the University of Bath, U.K., in 1999.  Before joining Avidity in April 2015, he was the RNA Vaccine Platform Leader at Novartis Vaccines, Inc., located in Cambridge, MA, for 6 years.  Dr. Geall joined Novartis in 2006 to lead the siRNA delivery efforts in the Pharmaceuticals AG division, but in 2008 moved to the Vaccines Research division to apply the non-viral delivery technologies developed for the systemic delivery of siRNA to the delivery of mRNA Vaccines.  Prior to this position, Dr. Geall was manager of the Pharmaceutics department at Vical in San Diego, where he led the formulation development of the company’s DNA vaccine program and was responsible for production of the gene delivery systems for clinical trials.